Cardiovascular events among recipients of hematopoietic stem cell transplantation

Abstract Background Allogeneic and autologous hematopoietic stem cell transplantation (HSCT) are potential curative treatments for several hematological malignancies (1). Survival after HSCT has improved over the last decade, but survivors remain at risk health issues transplantation. Cardiovascular complications increasingly recognized (2). diseases may be an important cause of mortality morbidity in patients owing to toxicities cancer therapies; however, incidence cardiovascular events (CVEs) this population not been completely characterized. The objective systematic review is summarize evidence on CVEs recipients. Methods Medline Embase were searched from inception December 2020 without language restriction. Two authors independently screened titles abstracts. Inclusion criteria were: cohort studies phase 3 randomized controlled trials that reported (i.e., heart failure, arrythmias, acute coronary syndrome, stroke) or death among adults who underwent a malignancy. All-cause mortality, relapse-related non-relapse-related (NRM) also collected. Studies which follow up period was started immediately excluded due immortal bias. Results Of 8151 nonduplicate articles, 30 including 14019 individuals post HSCT, 22 31049 allogeneic met inclusion criteria. cumulative first 100 days 9% arrhythmia atrial fibrillation) most common CVE. In recipients 100-day 3%, failure (HF) responsible 43% 10% NRM within days, respectively (Table 1). 4.96 per 1000-person years (95% CI; 4.21–5.80) long-term (beyond 100-days) HF CVE population. 1.90 CI: 1.59–2.24). frequently 2). Conclusion major non relapse especially days. Future needed identify factors specific Funding Acknowledgement Type funding sources: None.